References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J
Clin 2016;66:7-30.
2. Capitanio U, Montorsi F. Renal cancer. Lancet 2016;387:894-906.
3. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of
patients with stage IV renal cell carcinoma: memorial sloan-kettering
cancer center experience. Clin Cancer Res 2004;10:6302s-6303s.
4. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall
survival in patients with metastatic renal cell carcinoma treated with
vascular endothelial growth factor-targeted agents: results from a
large, multicenter study. J Clin Oncol 2009;27:5794-5799.
5. Klinghoffer Z, Yang B, Kapoor A, Pinthus JH. Obesity and renal cell
carcinoma: epidemiology, underlying mechanisms and management
considerations. Expert Rev Anticancer Ther 2009;9:975-987.
6. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological
evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591.
7. Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME, Russo P. Impact
of body mass index on survival of patients with surgically treated renal
cell carcinoma. J Urol 2006;175:46-52.
8. Steffens S, Grünwald V, Ringe KI, et al. Does obesity influence the
prognosis of metastatic renal cell carcinoma in patients treated with
vascular endothelial growth factor-targeted therapy? Oncologist
2011;16:1565-1571.
9. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic
investigation into the obesity paradox in renal cell carcinoma. J Natl
Cancer Inst 2013;105:1862-1870.
10. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, et al. Risk factor
paradox in wasting diseases. Curr Opin Clin Nutr Metab Care
2007;10:433-442.
11. Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a
predictor of prognosis in patients following hepatectomy for
hepatocellular carcinoma. Br J Surg 2013;100:1523-1530.
12. Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a Negative
Prognostic Factor After Curative Resection of Colorectal Cancer. Ann
Surg Oncol 2015;22:2663-2668.
13. Gu W, Wu J, Liu X, et al. Early skeletal muscle loss during target
therapy is a prognostic biomarker in metastatic renal cell carcinoma
patients. Sci Rep 2017;7:7587.
14. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical
implications of sarcopenic obesity in patients with solid tumours of the
respiratory and gastrointestinal tracts: a population-based study.
Lancet Oncol 2008;9:629-635.
15. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body
mass index and sarcopenia associated with dose-limiting toxicity of
sorafenib in patients with renal cell carcinoma. Ann Oncol
2010;21:1594-1598.
16. Gu W, Zhu Y, Wang H, et al. Prognostic value of components of body
composition in patients treated with targeted therapy for advanced renal
cell carcinoma: a retrospective case series. PLoS One 2015;10:e0118022.
17. Ladoire S, Bonnetain F, Gauthier M, et al. Visceral fat area as a
new independent predictive factor of survival in patients with
metastatic renal cell carcinoma treated with antiangiogenic agents.
Oncologist 2011;16:71-81.
18. Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density
predicts prognosis in patients with metastatic renal cell carcinoma
treated with targeted therapies. Cancer 2013;119:3377-3384.
19. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE.
Association of skeletal muscle wasting with treatment with sorafenib in
patients with advanced renal cell carcinoma: results from a
placebo-controlled study. J Clin Oncol 2010;28:1054-1060.
20. Powles T, Albiges L, Staehler M, et al. Updated European Association
of Urology Guidelines: Recommendations for the Treatment of First-line
Metastatic Clear Cell Renal Cancer. Eur Urol 2018;73:311-315.
21. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus
Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med
2019;380:1103-1115.
22. Yip SM, Heng DY, Tang PA. Review of the Interaction Between Body
Composition and Clinical Outcomes in Metastatic Renal Cell Cancer
Treated With Targeted Therapies. J Kidney Cancer VHL 2016;3:12-22.
Table 1. Clinical-pathological characteristics of patients
stratified according to gender.